Skip to content

#心血管代谢

Today 0 items
Oct 15Thu
  1. fda.gov46

    Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter

    Par Health USA is voluntarily recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level after particulate matter identified as cellulose, polystyrene, polyethylene terephthalate, stopper material and possibly stainless steel was detected. The affected lots, distributed nationwide to wholesalers and hospitals between December 30, 2024 and May 5, 2026, carry a risk of pulmonary emboli, blood vessel occlusion and vein wall inflammation. No adverse events have been reported; distributors and hospital pharmacies should stop use and return inventory through Inmar, Inc.

Oct 7Wed
  1. fda.gov40

    Rare Disease Drug Approvals

    FDA's CDER lists recent rare disease drug approvals on its Accelerating Rare Disease Cures Program page. In 2026 alone these include Camzyos for an inherited heart condition in children, Emcitate for MCT8 deficiency, Isembyld for muscle loss in spinal muscular atrophy, and Zanvastro for Alexander Disease, among others. The list spans 2021 to 2026 and links to the underlying FDA news releases.

Oct 2Fri
  1. fda.gov54

    FDA Approves First Heart Valve Designed to Grow with Children

    The FDA approved the Autus Size-Adjustable Valve, developed by Autus Valve Technologies and approved via Edwards Lifesciences, for pediatric patients with congenital pulmonary valve disease. It is the first heart valve that can be expanded after implantation, growing from about 13 millimeters to up to 22 millimeters, and the first U.S.-approved valve with polymeric rather than animal-derived leaflets. Approval rests on a study of 62 pediatric patients at 12 U.S. sites, with no deaths or clot-related complications; longer-term studies are under way.

    Why it matters: First FDA-approved expandable pediatric heart valve may cut repeat open-heart surgeries in children.

Oct 1Thu
  1. fda.gov51

    FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

    The FDA is warning patients and health care professionals about risks from unapproved compounded versions of GLP-1 drugs, including semaglutide and tirzepatide, used for weight loss, because these products are not reviewed for safety, effectiveness or quality. The agency states that retatrutide and cagrilintide cannot be used in compounding under federal law, has warned telehealth companies, API distributors and outsourcing facilities over retatrutide, and set up import alert 66-80 to stop GLP-1 APIs with quality concerns at the border. It also advises discarding multi-dose vials within 28 days of first use and not using injectable GLP-1 drugs that arrive warm.

  2. fda.gov61

    FDA approves first drug to improve functional capacity and symptoms in children with rare inherited heart condition

    The FDA approved Camzyos (mavacamten) as the first treatment to improve functional capacity and symptoms in children with symptomatic obstructive hypertrophic cardiomyopathy, extending approval to pediatric patients weighing at least 30 kg, after adult approval in 2022. Efficacy was supported by the phase 3 SCOUT-HCM trial in 44 patients aged 12-18, where once-daily dosing for 28 weeks significantly reduced the Valsalva LVOT gradient versus placebo. The drug carries a boxed warning for heart failure risk and is available only through the Camzyos REMS program.

    Why it matters: First pediatric approval for symptomatic oHCM, backed by phase 3 data in adolescents.

Sep 4Fri
  1. ema.europa.eu45

    Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026

    EMA's Pharmacovigilance Risk Assessment Committee has begun a review of all injectable iron-containing medicines over risks of hypophosphataemia and related bone problems such as osteomalacia. The review was triggered by reports questioning the effectiveness of current risk-minimisation measures for ferric carboxymaltose products, including serious cases after only one or two doses in people without recognised risk factors. PRAC will assess the benefit-risk balance and decide whether changes to marketing authorisations are needed.

    Why it matters: A EU-wide safety review of all injectable iron medicines could change prescribing and product information for iron deficiency anaemia.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org